MASSACHUSETTS: Burns & Levinson and Viridian Capital Advisors will co-host “The Cannabis Industry: Growth Opportunities for Professionals, Operators and Investors,” an invitation-only event that will explore opportunities within the rapidly growing multi-billion dollar cannabis industry for professional investors and entrepreneurs. The conference will be held on October 17, 2017 from 8:00 a.m. to 6:00 p.m. EDT at the Hilton Boston/Dedham Hotel.
This investor-focused conference is intended to help venture capitalists, private equity firms, and single- and multi-family offices learn more about cannabis investments as an alternative asset class poised to provide non-correlative returns to many other types of investments. As legalization continues to spread, cannabis is opening new doors in traditional markets – biotech/pharma, real estate, software, consumer packaged goods and branded products, among others – long favored by institutional investors.
The event will feature four in-depth panel discussions, networking opportunities, and a keynote speech by Kris Krane, co-founder and managing partner of 4Front Advisors and president of 4Front Ventures. Krane helped draft Massachusetts Ballot Question 4 – Legalize Marijuana in the 2016 election, and prior to forming 4Front, he served as director of client services for CannBe, which was a pioneer in developing best practices within the marijuana industry. Krane will discuss future opportunities and risks in the marijuana industry in New England and across the country.
“We believe this is the first conference in New England with a specific focus on institutional investing in the cannabis industry,” said Frank A. Segall, co-chair of the Cannabis Business Advisory Group at Burns & Levinson. “Cannabis is already a multi-billion dollar industry, and its growth is projected to potentially increase at an exponential and possibly unprecedented rate over the coming years.”
“There are many promising cannabis industry sectors that are poised for significant growth and return on investment. We want to help the investment community understand the risks and rewards, and give them the tools they need to take advantage of these opportunities,” added Scott Moskol, who co-chairs Burns’ Cannabis Business Advisory Group with Segall.
Specific breakout sessions will include:
•The New England Experience – A discussion on how cannabis business operators across New England have navigated the sometimes tempestuous legal waters to build successful businesses including raising capital and investments.
•Follow the Money: Analyzing Capital Flow into the Legal Cannabis Industry – A look at the capital infusions necessary to launch, operate, or invest in the cannabis space, with Viridian providing deal-data insight regarding capital raises and M&A activity.
•Sector Focus: Cannabinoid-Based Biopharmaceuticals and Personalized Medicine – A deep dive into the research, development, and commercialization of cannabis-based pharmaceuticals, an industry sub-sector that could hold the greatest potential value over time.
•The Future of Cannabis – A critical review of key legal and regulatory changes on the horizon and the expected impact for investors and capital providers.